New antifungal agents in pediatric practice

Indian Pediatrics

Volumn 46, Issue 3, 2009, Pages 225-231

  Das, S ^a   Shivaprakash, M R ^b   Chakrabarti, A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antifungal; Antimicrobial; Mycoses; Treatment

Indexed keywords

ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; HMR 3270; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDEMIA; CHEILITIS; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EPISTAXIS; FEVER; FUNGAL CELL; FUNGAL STRAIN; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MEDICAL PRACTICE; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MUCOSA INFLAMMATION; MYCOSIS; PEDIATRICS; PHOTOPHOBIA; RASH; REVIEW; THROMBOPHLEBITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANTIFUNGAL AGENTS; AZOLES; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; HUMANS; MYCOSES; PEDIATRICS;

EID: 62949238355     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Blyth CC, Palasanthiran P, O'Brien T. Antifungal therapy in children with invasive fungal infections: A systematic review. Pediatrics 2007; 119: 772-784.
2. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case- fatality rate: systematic review of literature. Clin Infect Dis 2001; 32: 358-366.
4. Frattarelli DA, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004; 64: 949-968.
5. O'Grady MJ, Dempsey EM. Antifungal prophylaxis for the prevention of neonatal candidiasis? Acta Pediatrica 2008; 97: 430-433.
6. Roy A, Maiti PK, Adhya S, Bhattacharya A, Chakraborty G, Ghosh E, et al. Neonatal candidemia. Indian J Pediatr 1993; 60: 789-801.
7. Vaideeswar P, Sivaraman A, Deshpande JR. Neonatal candidal endocarditis - a rare manifestation of systemic candidiasis. Indian J Pathol Microbiol 1999; 43: 165-168.
8. Chakrabarti A, Singh K, Narang A, Singhi S, Batra R, Rao KL, et al. Outbreak of Pichia anomala infection in the pediatric service of a tertiary-care center in Northern India. J Clin Microbiol 2001; 39: 1702-1706.
9. Richardson M, Lass Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14 (Suppl 4): 5-24.
10. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 (Suppl 2): 8-24.
11. Almirante B, Rodriguez D. Antifungal agents in neonates. Issues and recommendations. Pediatr Drugs 2007; 9: 311-321.
12. Walsh TJ, Karlsson MD, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple- dose administration. Antimicrob Agent Chemother 2004; 48: 2166-2172.
13. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008; 93: 578-581.
14. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
15. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
16. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am 2005; 19: 603615.
17. Kohli V, Taneja V, Sachdev P, Jorhi R. Voriconazole in newborns. Indian Pediatr 2008; 45: 236-238.
18. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-4066.
19. Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 780-782.
20. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133.
21. Raad, II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
22. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agent Chemother 2007; 51: 812-818.
23. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004; 42: 3137-3141.
24. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18: 484-489.
25. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekman E, Brown T, et al. Single ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100 and 200 milligrams) and oral administrations (100, 200 and 400 milligrams) of its prodrug BAL8557, in healthy volunteers. Antimicrob Agent Chemother 2006; 50: 279-285.
26. Mouton JW, Verweij PE, Warn P, Denning D, Heep M, Isham N, et. al. In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. Mycoses 2005; 48: 58-59.
27. Parekh A, Dubey AP, Samanta D. Caspofungin. Indian Pediatr 2008; 45: 905-910.
28. Heresi GP, Gerstmann DR, Blumer JL, van den Anchor J, Kearns GL, Reed MD, et al. Pharmacokinetic study of micafungin in premature neonates [abstract]. In: Pediatric Academic Societies Meeting; 3-6 May 2003; Seattle. The Woodlands: Pediatric Academic Societies; 2003. Abstract 83.
29. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agent Chemother 2005; 49: 3317-3324.
30. Townsend R, Bekersky I, Buell DN, Buell NS. Pharmacokinetic evaluation of echinocandin FK463 in pediatric and adult patients [abstract]. In: Focus on Fungal Infections 11; 14-17 March 2001; Washington, DC. Alpharetta: Imedex; 2001. Abstract 024.
31. Kontoyannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdiere M, Denning DW, et al.. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infect Dis 2008 Oct 8 [Epub].
32. Ostrosky-Zeichner L, Kontoyannis D, Raffalli J, Mullane KM, Vasquez J, Anaissie, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005 ; 24: 654-661
33. Benjamin DKJ, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, et al. Safety and pharmacokinetics of intravenous Anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agent Chemother 2006; 50: 632-638.
34. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006; 44: 4342-4344.
35. Krcmery V, Kalavsky E. Antifungal discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent Patents Anti-Infect Drug Disc 2007; 2 : 182-187.